Specialty × MAC Jurisdiction Intelligence
OncologyCMS & MAC AlertsPalmetto GBA · Jurisdictions JJ, JM
Every CMS transmittal, Palmetto GBA LCD revision, Federal Register notice, and OIG alert affecting Oncology billing teams in Georgia, North Carolina, South Carolina, Tennessee, Virginia, West Virginia. Signal-scored and updated daily.
Active alerts
12
Critical / High
10
MAC jurisdiction
JJ, JM
Highest-risk CPT
CPT 96413
Recent Oncology alerts under Palmetto GBA
10 of the 12 most recent Oncology reimbursement alerts are Critical/High-severity for Palmetto GBA (Jurisdictions JJ, JM) billing teams. Each links to the source CMS/MAC document with the codes to review and the action to take.
- FDA Approval: RASONQUE (DARAXONRASIB) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: VOBRIG (LEUPROLIDE ACETATE) — Type 5 - New Formulation or New ManufacturerSep 3, 2026
- FDA Approval: LIBTAYO (CEMIPLIMAB-RWLC) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: BAVENCIO (AVELUMAB) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: UNLOXCYT (COSIBELIMAB) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: IMJUDO (TREMELIMUMAB) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: PENPULIMAB KCQX (PENPULIMAB) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: LOQTORZI (TORIPALIMAB-TPZI) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: TEVIMBRA (TISLELIZUMAB-JSGR) — Type 1 - New Molecular EntityAug 28, 2026
- FDA Approval: ZIIHERA (ZANIDATAMAB-HRII) — Type 1 - New Molecular EntityAug 28, 2026
- Proposed LCD DL40427: MolDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic Malignancies — NoridianNoridian · Aug 27, 2026
- Proposed LCD DL40435: MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal Carcinoma — NoridianNoridian · Aug 27, 2026
Signal intelligence — Oncology × Palmetto GBA
Highest-risk CPT code
CPT 96413
Chemotherapy administration, intravenous push
View full CPT alert profilePalmetto GBA jurisdiction
JJ, JM
Covers Georgia, North Carolina, South Carolina, Tennessee, Virginia, West Virginia. Every oncology LCD revision, CMS transmittal, and Federal Register notice affecting these states is signal-scored and surfaced here daily.
View all 12 active alerts for Oncology under Palmetto GBA
Full alert text, action recommendations, effective date deadlines, MAC LCD links, and signal score rationale — updated daily.
About Palmetto GBA (Jurisdictions JJ, JM)
Palmetto GBA is the Medicare Administrative Contractor responsible for processing Medicare Part A and Part B claims in Jurisdictions JJ, JM, covering Georgia, North Carolina, South Carolina, Tennessee, Virginia, West Virginia.Palmetto GBA issues Local Coverage Determinations (LCDs) that define coverage criteria, ICD-10-CM diagnosis code requirements, and CPT billing guidelines for Oncology procedures within its jurisdiction. CLV Intelligence monitors Palmetto GBA's LCD publication feed, provider bulletin archives, and CMS contractor-specific transmittals daily.
Oncology alerts in other MAC jurisdictions
Get weekly Oncology alerts for Palmetto GBA — free
No credit card required. Unsubscribe any time.
Frequently asked
- What are the recent CMS updates for Oncology under Palmetto GBA MAC?
- According to CLV Intelligence data, updated September 3, 2026, there are currently 12 active CMS and MAC reimbursement policy alerts for Oncology under Palmetto GBA (Jurisdictions JJ, JM). Of these, 10 are classified Critical or High priority based on signal scoring of source authority, effective-date urgency, and document type. Alerts originate from Palmetto GBA Local Coverage Determinations (LCDs), CMS transmittals, Federal Register proposed and final rules, and OIG compliance publications. CLV Intelligence monitors all Palmetto GBA publications daily and assigns a signal score (0–100) to surface the changes most likely to affect coding accuracy and reimbursement.
- How many active audit alerts exist for Oncology CPT codes under Palmetto GBA?
- According to CLV Intelligence data, 12 active reimbursement and policy alerts currently affect Oncology CPT codes monitored under Palmetto GBA (Jurisdictions JJ, JM). 10 of these alerts carry a Critical or High signal score, indicating elevated compliance risk or near-term effective dates requiring timely coding review. The highest-risk CPT code currently flagged in the Oncology alert set is CPT 96413 (Chemotherapy administration, intravenous push), which appears in Palmetto GBA LCD and CMS billing guidance revisions. CLV Intelligence cross-references each alert against the HCPCS and CPT code sets to surface procedure-level exposure for Oncology billing teams.
- Which MAC jurisdiction covers Oncology billing for practices in the Palmetto GBA region?
- Palmetto GBA administers Medicare Part A and Part B claims for practices in Jurisdictions JJ, JM. For Oncology providers, Palmetto GBA issues Local Coverage Determinations (LCDs) that define coverage criteria, billing requirements, ICD-10-CM diagnosis code ranges, and CPT procedure code guidelines applicable to Medicare claims in its jurisdiction. According to CLV Intelligence data, Palmetto GBA monitors 12 open Oncology alerts as of September 3, 2026. Practices in the Palmetto GBA jurisdiction should monitor LCD revisions at Palmetto GBA's provider portal and through aggregated daily alerting services such as CLV Intelligence.
- Is CPT 96413 currently under CMS or MAC review for Oncology?
- According to CLV Intelligence data, CPT 96413 (Chemotherapy administration, intravenous push) is currently flagged as a high-signal procedure code within the Oncology alert set monitored under Palmetto GBA (Jurisdictions JJ, JM). CMS and MAC contractors regularly review high-volume procedure codes for coverage criteria changes, NCCI edit revisions, medical necessity documentation requirements, and fee schedule adjustments. CLV Intelligence assigns CPT 96413 an elevated signal score based on the volume and recency of policy documents referencing this code. Oncology coding teams should review the latest Palmetto GBA LCD and CMS transmittals affecting CPT 96413 before claim submission to avoid denials or post-payment audits.